* Alzamend Neuro Inc ALZN.OQ ALZN.O is expected to show
no
change in quarterly revenue when it reports results for the
period ending July 31 2023
*
* LSEG's mean analyst estimate for Alzamend Neuro Inc is
for a
loss of 67 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Alzamend
Neuro
Inc is $56.25, above its last closing price of $1.11.
This summary was machine generated December 8 at 21:12 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)